IgA nephropathy is the world's most common primary glomerulonephropathy. Recent evidence in a rat model implicated excessive production of
oxygen-
free radicals in the pathogenesis and suggested that
vitamin E-treatment ameliorated progression. We studied this
antioxidant therapy on the glomerular filtration rate (GFR),
proteinuria and
hematuria in biopsy-proven
IgA nephropathy in children. The
duration of treatment or placebo was 2 years, with
vitamin E treatment consisting of 400 IU/day in children weighing <30 kg, and twice that dose for those >30 kg. We measured GFR at entry, midpoint and exit. At baseline and at 4-month intervals after randomization, urinary
protein/
creatinine ratios and urinalysis were examined. The mixed model procedure with log transformation was used in data analysis to test treatment difference as well as the potential time effect. Fifty-five patients were randomized and 38 completed at least 1 year of follow-up. At entry, the clinical characteristics were not different between the treatment and placebo groups. There was a trend toward better preservation of GFR in
vitamin E-treated versus placebo patients, 127+/-50 vs. 112+/-31 ml/min/1.73 m(2), respectively ( P=0.09). The urinary
protein/
creatinine ratio was significantly lower in the
vitamin E-treated group vs. placebo; 0.24+/-0.38 vs. 0.61+/-1.37 ( P<0.013). However, there was no difference in the prevalence of
hematuria between the groups.
Vitamin E treatment in our study patients was associated with significantly lower
proteinuria, but no effect on
hematuria. While there was a trend toward stabilization of GFR in the
vitamin E-treated patients, long-term treatment and follow-up are needed to determine whether
antioxidant therapy is associated with preservation of renal function in
IgA nephropathy.